US FDA Form 483 inspection letters no cause for panic
This article was originally published in RAJ Devices
A post-inspection letter from the US Food and Drug Administration raising concerns about a device company’s facilities may be unwelcome, but it could also be seen as an opportunity, according to one expert.
You may also be interested in...
Vydaqel saw its uptake take off in the US last year. UK’s NICE to pass judgement on cost effectiveness by June.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.
Perrigo is launching in the UK an OTC sildenafil generic to compete with Pfizer's erectile dysfunction drug Viagra Connect.